# Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

> **NCT07132567** · — · RECRUITING · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Mycosis Fungoides
- Sezary Syndrome

## Interventions

- **DRUG:** Poteligeo 20mg

## Key facts

- **NCT ID:** NCT07132567
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-02
- **Primary completion:** 2028-09
- **Final completion:** 2028-11
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132567, "Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07132567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*